Dementia Drugs Part 4 PDF

\#\#\# Slide 19 - NMDA Blockers 1\. \*\*What is the mechanism of action of Memantine in Alzheimer\'s disease?\*\* \- A) Dopamine receptor antagonist \- B) NMDA receptor antagonist \- C) Acetylcholine receptor agonist \- D) Serotonin receptor antagonist \*\*Answer\*\*: B) NMDA receptor antagoni...

\#\#\# Slide 19 - NMDA Blockers 1\. \*\*What is the mechanism of action of Memantine in Alzheimer\'s disease?\*\* \- A) Dopamine receptor antagonist \- B) NMDA receptor antagonist \- C) Acetylcholine receptor agonist \- D) Serotonin receptor antagonist \*\*Answer\*\*: B) NMDA receptor antagonist 2\. \*\*Memantine is indicated for which stage of Alzheimer\'s disease?\*\* \- A) Mild \- B) Moderate to severe \- C) Early onset \- D) Asymptomatic \*\*Answer\*\*: B) Moderate to severe 3\. \*\*What side effect is most commonly associated with NMDA blockers like Memantine?\*\* \- A) Dizziness \- B) Increased appetite \- C) Bradycardia \- D) Weight gain \*\*Answer\*\*: A) Dizziness \#\#\# Slide 20 - Clinical Tips 4\. \*\*When should Alzheimer\'s medications be tapered off?\*\* \- A) Rapid improvement in cognition \- B) No improvement after 3-6 months \- C) Asymptomatic stage \- D) Early onset diagnosis \*\*Answer\*\*: B) No improvement after 3-6 months 5\. \*\*In which patients might it be recommended to discontinue Alzheimer\'s medications?\*\* \- A) Patients with trouble swallowing \- B) Patients with depression \- C) Patients with mild cognitive impairment \- D) Patients in the early stages of Alzheimer's \*\*Answer\*\*: A) Patients with trouble swallowing 6\. \*\*Which tool is commonly used to monitor the cognitive function in Alzheimer\'s disease?\*\* \- A) Glasgow Coma Scale \- B) MMSE (Mini-Mental State Exam) \- C) ECG \- D) FIM score \*\*Answer\*\*: B) MMSE \#\#\# Slide 21 - Biologics 7\. \*\*Which biological agent is used to target beta-amyloid plaques in Alzheimer\'s?\*\* \- A) Donepezil \- B) Aducanumab \- C) Memantine \- D) Rivastigmine \*\*Answer\*\*: B) Aducanumab 8\. \*\*What type of imaging is required before initiating Aducanumab therapy?\*\* \- A) X-ray \- B) PET scan \- C) MRI \- D) CT scan \*\*Answer\*\*: B) PET scan 9\. \*\*What was a major reason for the early stoppage of phase III trials of Aducanumab?\*\* \- A) Severe side effects \- B) Lack of clinical benefit \- C) Financial issues \- D) Inconvenience to patients \*\*Answer\*\*: B) Lack of clinical benefit \#\#\# Slide 22 - Biologics (Side Effects) 10\. \*\*What is a common side effect of biologics used in Alzheimer's treatment such as Aducanumab?\*\* \- A) Amyloid-related imaging abnormalities (ARIA) \- B) Hypertension \- C) Seizures \- D) Liver failure \*\*Answer\*\*: A) Amyloid-related imaging abnormalities (ARIA) 11\. \*\*Which of the following is NOT a typical side effect of Aducanumab?\*\* \- A) Infusion reactions \- B) Microhemorrhage \- C) Weight gain \- D) Superficial siderosis \*\*Answer\*\*: C) Weight gain 12\. \*\*What is the estimated annual cost of Aducanumab treatment?\*\* \- A) \$5,000 \- B) \$10,000 \- C) \$30,000 \- D) \$50,000 \*\*Answer\*\*: C) \$30,000 \#\#\# Slide 23 - Caprylidene 13\. \*\*Caprylidene is used as a medical food for which purpose in Alzheimer\'s patients?\*\* \- A) Decrease amyloid plaques \- B) Provide ketone bodies for energy \- C) Increase acetylcholine levels \- D) Boost serotonin production \*\*Answer\*\*: B) Provide ketone bodies for energy 14\. \*\*Caprylidene works by compensating for impaired processing of what substance in the brain?\*\* \- A) Glucose \- B) Protein \- C) Fatty acids \- D) Insulin \*\*Answer\*\*: A) Glucose 15\. \*\*What is required to diagnose glucose uptake impairment in Alzheimer's patients?\*\* \- A) MRI \- B) CT scan \- C) PET scan \- D) EEG \*\*Answer\*\*: A) MRI \#\#\# Slide 25 - Alzheimer\'s Disease Behavioral Symptoms 16\. \*\*Which class of drugs is commonly used to treat agitation in Alzheimer's disease?\*\* \- A) SSRIs \- B) MAO inhibitors \- C) Dopamine agonists \- D) Anticonvulsants \*\*Answer\*\*: A) SSRIs 17\. \*\*What is a typical non-pharmacologic approach to managing behavioral symptoms in Alzheimer's disease?\*\* \- A) Sleep deprivation \- B) Physical restraints \- C) Cognitive-behavioral therapy \- D) Electroconvulsive therapy \*\*Answer\*\*: C) Cognitive-behavioral therapy 18\. \*\*Which antipsychotic is recommended for managing psychosis in Alzheimer's patients?\*\* \- A) Risperidone \- B) Fluoxetine \- C) Haloperidol \- D) Valproate \*\*Answer\*\*: A) Risperidone \#\#\# Slide 26 - Current Alzheimer's Treatment Approach 19\. \*\*Which drug is often added during the moderate stages of Alzheimer's disease?\*\* \- A) Rivastigmine \- B) Memantine \- C) Donepezil \- D) Tacrine \*\*Answer\*\*: B) Memantine 20\. \*\*What is the rationale for eliminating drugs with anticholinergic effects in Alzheimer's treatment?\*\* \- A) They enhance cognitive decline \- B) They reduce cardiovascular risks \- C) They decrease sleep disturbances \- D) They prevent seizures \*\*Answer\*\*: A) They enhance cognitive decline 21\. \*\*Which class of drugs should be avoided in Alzheimer\'s patients due to sedative effects?\*\* \- A) SSRIs \- B) Sedative-hypnotics \- C) Cholinesterase inhibitors \- D) NMDA antagonists \*\*Answer\*\*: B) Sedative-hypnotics \#\#\# Slide 30 - Multi-Factorial Therapeutic Program 22\. \*\*Which of the following is NOT a strategy to optimize brain health in Alzheimer's disease?\*\* \- A) Diet and nutrition \- B) Physical exercise \- C) Medication reduction \- D) Stress management \*\*Answer\*\*: C) Medication reduction 23\. \*\*Which factor is crucial for managing insulin resistance in Alzheimer's disease?\*\* \- A) Supplements \- B) Physical exercise \- C) Sleep aids \- D) Cognitive therapy \*\*Answer\*\*: B) Physical exercise 24\. \*\*Which of the following should be monitored to ensure better outcomes in Alzheimer\'s patients?\*\* \- A) Vitamin C levels \- B) Cognitive stimulation \- C) Glycemic control \- D) Cholesterol levels \*\*Answer\*\*: C) Glycemic control \#\#\# Slide 36 - ReCODE Program 25\. \*\*What is the goal of the ReCODE program in Alzheimer's disease?\*\* \- A) Cure Alzheimer's disease \- B) Improve cognitive and metabolic function \- C) Reverse beta-amyloid plaque \- D) Prevent seizures \*\*Answer\*\*: B) Improve cognitive and metabolic function 26\. \*\*Which cognitive assessment tool was used in the ReCODE program?\*\* \- A) MMSE \- B) MoCA \- C) ADAS-Cog \- D) CIBIC \*\*Answer\*\*: B) MoCA 27\. \*\*What was a significant finding of the ReCODE program after 12 months of intervention?\*\* \- A) Disease reversal \- B) Cognitive decline prevention \- C) Cognitive stabilization or improvement \- D) Complete cognitive restoration \*\*Answer\*\*: C) Cognitive stabilization or improvement